Complementary and alternative medicines (CAMs), in particular herbal medicines, are commonly used by cancer patients in conjunction with chemotherapy treatment for their anticancer properties and supportive care. However, the effects of many of these herbs are not well-documented due to limited studies done on them. Severe herb-drug interactions (HDIs) have been recorded in some cases, and failure to recognize these harmful HDIs can lead to dire consequences in cancer patients. This study discusses clinically-relevant interactions between anticancer drugs (ACDs) and herbs classified into 7 categories: cancer treatment and prevention, immune-system-related, alopecia, nausea and vomiting, peripheral neuropathy and pain, inflammation, and fatigue. Some promising patents which contain these herbs and thus may manifest these interactions are also presented in this article. Pharmacokinetic interactions involved mainly induction or inhibition of the cytochrome P450 isozymes and p-glycoprotein, while pharmacodynamic interactions were related to increased risks of central nervous system-related effects, hepatotoxicity and bleeding, among others. Clinicians should be vigilant when treating cancer patients who take CAMs with concurrent chemotherapy since they face a high risk of HDIs. These HDIs can be minimized or avoided by selecting herb-drug pairs which are less likely to interact. Furthermore, close monitoring of pharmacological effects and plasma drug levels should be carried out to avoid toxicity and ensure adequate chemotherapeutic coverage in patients with cancer.
INTRODUCTION
Cancer is a highly prevalent health problem with increasing incidence worldwide. It is a leading cause of death in the United States (US), and is only superseded by heart disease [1] . In 2007, one in eight deaths was due to cancer [2] , while in 2008, the number of new cancer cases was expected to be about 1,437,180 with more than 565,000 deaths [1] . It is estimated that the global burden of cancer is expected to grow to 27 million new cancer cases and 17.5 million cancer deaths by 2050 [2] . This is a cause for concern considering that cancers caused by cigarette smoking and alcohol use can be prevented, while others such as breast cancers can be avoided by regular screening examinations.
Patients with cancer can be managed through surgery, radiotherapy, immunotherapy, chemotherapy, or a combination of these [1] . However, the use of complementary and alternative medicines (CAMs), including traditional Chinese medicines (TCMs), has been gaining popularity in an increasing number of patients with cancer in their course of therapy [3, 4] . CAM usage in the general US population has increased over the past 20 years, reaching 36% in 2002 [4] , ACD-CAM interactions may potentially be harmful to patients due to the narrow therapeutic indices of ACDs. HDIs can lead to either an increased toxicity or sub-therapeutic effects. The potential for an interaction is ~6% when two drugs are prescribed concurrently, and the probability increases as more drugs are used concurrently [16] . Little information exists for CAMs. However, a similar deduction can be drawn from this trend regarding the likelihood of ACD-CAM interactions. In addition, some CAM products may contain multiple pharmacologically active constituents, which may further increase the risk of ACD-CAM interactions. These interactions can lead to significant clinical consequences and possibly even fatal outcomes [17] . HDIs can play an important role in clinical decision making in 3 situations: (a) adding an interacting herb to existing chemotherapy; (b) adding a chemotherapeutic treatment regime to the interacting herb; and (c) removing an interacting herb from long-term chemotherapy.
Drug interactions can be pharmacokinetic or pharmacodynamic in nature. Although drug interactions typically refer to drug-drug interactions, other interactions such as fooddrug or herb-drug interactions also exist, and are important considerations in the therapeutic care of a patient. Pharmacokinetic interactions usually involve changes in absorption, distribution, metabolism or elimination of a drug, which can be due to either enzyme induction or inhibition [18] . On the other hand, pharmacodynamic interactions can result in antagonistic, additive or synergistic effects [18] . Albeit the fact that pharmacodynamic interactions form the basis of the multiple-agent chemotherapy cocktails used in improving the clinical response in patients with cancer, other undesirable clinical consequences can also occur in these patients [18, 19] . For example, the concomitant use of trastuzumab and anthracyclines can result in an increased risk of cardiac toxicities [20] , while the combined use of rituximab and cisplatin can also predispose patients to severe renal toxicity, including acute renal failure [21] .
Clinicians must be vigilant when treating patients with cancer who are concurrently on both chemotherapy and CAMs so as to avoid unwanted toxicities and inadequate drug exposures due to the HDIs. Hence, this review aims to highlight the common types of interactions that are observed between ACDs and CAM herbs which are indicated for cancer treatment, prevention, and supportive care. With the advent of new CAM products and supplements in the consumer market, this paper will also illustrate some HDIs that are clinically-relevant in patients with cancer through a discussion of how these HDIs are related to CAM products that have recently been patented. Although this review is not exhaustive, it is intended to increase the clinicians' awareness of potential HDIs, so that appropriate adjustments can be made to optimize the outcomes of chemotherapy. A holistic view comprising the risks and benefits of ACD-CAM combinations should be considered by clinicians in the treatment of patients with cancer.
SEARCH STRATEGY
A list of ACDs and CAMs was compiled from a total of 14 sources, which consisted of reference books and online databases. These included the British National Formulary (53 rd ed.) [22] , BC Cancer Agency (BCCA) Cancer Drug
Manual [23] , Lexi-Comp's Drug Information Handbook (15 th ed.) [24] , Lexi-Comp's Drug Information Handbook for Oncology (6 th ed.) [25] , PharmGKB [26] , Pharmacology and Applications of Chinese Materia Medica [27] , Aetna Intelihealth ® [28] , TCM Assistant [29] , Memorial SloanKettering [30] , Micromedex ® v.5.1. [31] , Natural Medicines Comprehensive Database (10 th ed.) [32] , Drugs.com [33] , Caremark Drug Interactions [34] and DoubleCheckMD [35] . The first 11 sources were used to gather information on the pharmacokinetics of ACDs, characteristics and clinical indications of CAMs, while the latter 6 were used to compile interaction data with ACDs. Interaction checkers were used for the gathering of HDI information where applicable. When there was no interaction information available through the checkers, the monographs of the ACDs and CAMs would be consulted instead. In addition, published literature from PubMed was also used to supplement our review based on the following keywords: "anticancer drugs", "chemotherapy", "complementary and alternative medicines", and "herb-drug/ drug-herb interactions". Alternative therapies (e.g. Ayurveda), substances with limited documentation on their medicinal properties (e.g. alkaline water), vitamins and minerals, and commercial supplements were excluded from our search.
A list of patents containing CAM products was also collated from the patent databases by the United States Patent and Trademark Office [36, 37] , European Patent Office [38] , Free Patents Online [39] and Google Patents [40] , with the keywords "anticancer herbs" and "complementary and alternative medicines". Only patents in which the CAM constituents were documented were included in our search. Patents were limited to only those that were approved from the year 2000, and had to include at least one of our compiled CAMs based on our search strategy previously described. Patent applications that were submitted but not approved with a patent number were excluded from our search.
RESULTS

Classification of Herb-Drug Interactions Between Anticancer Drugs and Complementary and Alternative Medicines
This paper identifies the clinically important HDIs between ACDs used in chemotherapy and CAMs which have indications in cancer treatment, prevention and supportive care. The CAMs are categorized into 7 classes based on their indications in cancer therapy: (a) cancer treatment or prevention, (b) immune-system-related, (c) alopecia, (d) nausea and vomiting, (e) peripheral neuropathy and pain, (f) inflammation, and (g) fatigue syndrome. As such, the rest of this paper discusses the HDIs in greater detail based on these 7 categories of CAMs. Patents which fall within these categories will also be listed in their respective sections. Tables 1 to 3 provide a summary of all the ACDs, CAMs and patents that were identified in our review. In addition, the HDIs that were identified based on our findings are detailed in Table 4 , sorted according to alphabetical order of the CAMs. The active constituents of certain CAMs that are deemed responsible for these HDIs are also provided in Fig. (1) [ [169] [170] [171] [172] [173] [174] [175] [176] , where applicable.
HERB-DRUG INTERACTIONS BASED ON CANCER INDICATIONS Cancer Treatment and Prevention
A large proportion of CAMs identified in this article are indicated for cancer treatment and prevention Table 2 . Among these, a number have been identified to have interactions with ACDs. One common herb used for its adaptogenic effects is ginseng. The major active components in ginsengs are the triterpene glycosides called ginsenosides, of which more than 30 different ginsenosides are known [169] . The antiproliferative effects of American ginseng (Panax quinquefolius) has been demonstrated in human breast cancer cells [174] , and epidemiological studies have also indicated that it can improve survival and quality of life in breast cancer patients [175] . On the other hand, Asian ginseng (Panax ginseng) has also been researched for its use in a wide variety of cancers and its effects on the immune system [84, 176, 177] . These ginsengs may precipitate an interaction with ACDs that have monoamine oxidase (MAO) inhibitory activity, such as procarbazine. Several case reports of patients suffering from insomnia, headaches, tremors and hypomania during concomitant administration of ginseng and phenelzine have been published [17, [85] [86] [87] [88] . This is a result of the potentiation of the MAO inhibition effects of phenelzine. Thus, this combination should be avoided in cancer patients undergoing procarbazine therapy. Immune-system-related Increased doses may be required to achieve therapeutic efficacy.
The manufacturer recommends that a dose increase from 25 mg/week up to 50mg/week be considered if temsirolimus is coadministered with strong CYP3A4 inducers, and the dose be adjusted back upon discontinuation of the inducer ( The manufacturer recommends that a dose reduction to 12.5 mg/week or a dose increase to 50mg/week be considered if temsirolimus is coadministered with strong CYP3A4 inhibitors or inducers respectively. The temsirolimus dose should be adjusted back upon discontinuation of the inhibitor or inducer, and a washout period of ( Manufacturer information recommends the following:
(a) Erlotinib dose should be increased as tolerated at 2-week intervals to a maximum of 450mg, and the dose reduced upon inducer discontinuation.
(b) Gefitinib dosage may be increased to 500 mg/day in the absence of severe adverse reactions, and decreased accordingly when the inducer is discontinued ( The manufacturer recommends that a dose reduction to 12.5 mg/week be considered if temsirolimus is coadministered with strong CYP3A4 inhibitors, and a washout period of approximately 1 week be allowed before the temsirolimus dose be adjusted back upon discontinuation of the inhibitor ( American and Asian ginsengs, together with several other herbs which possess effects on glycemic control such as bitter melon, bilberry fruit, burdock, fenugreek and garlic [44] , may theoretically also interact with rituximab resulting in a potentiation of hypoglycemia [24, 25] . Hypoglycemia is a rare adverse effect of rituximab which was previously identified in a 50-year-old female undergoing chemotherapy for non-Hodgkin's lymphoma, and its mechanism is not well understood [43] . Patients who are on rituximab therapy and taking ginsengs concurrently could be predisposed to a risk of hypoglycemia since ginsenoside Re, which is present in both American and Asian ginsengs, was shown to reduce fasting blood glucose levels in mice [83] . Clinicians treating these patients should be aware of the signs and symptoms
(-)-epigallocatechin-3-gallate in green tea Ginsenosides in ginseng Genistein in soy which indicate rituximab-induced hypoglycemic effects, such as fatigue, sweating and restlessness.
Siberian ginseng (Eleutherococcus senticosus) is also adaptogenic in nature, and it possesses anticancer and immunomodulatory effects [178] . This herb has been postulated to inhibit the cytochrome P450 (CYP450) system, mainly the CYP1A2, 2C9 and 3A4 isozymes [89] , which leads to a pharmacokinetic interaction of increased plasma levels of ACDs that are substrates of these isozymes. However, in vitro studies have also suggested the opposite, that the eleutherosides (active components) in Siberian ginseng are unlikely to cause inhibition of these isozymes [90] . Garlic (Allium sativum) is another herb which shows anticancer effects in human cancer cell lines [179, 180] . It is also linked with possible interactions resulting from induction of CYP3A4 and p-glycoprotein [67, 69] , but the evidence for its interactions have been contradictory as well. Garlic inhibits CYP2C9, 2C19 and 3A4 in vitro [68, 70] , but results in a decrease in plasma levels of saquinavir (a CYP3A4 substrate) in vivo instead [69] . Green tea (Camellia sinensis), a CAM which has anticarcinogenic and chemoprotective effects [181] , is familiar to most cancer patients as well. Its anticancer effects are due to epigallocatechin gallate, a major constituent, which suppresses tumor invasion and angiogenesis [170] . in vitro and animal studies have shown that green tea non-specifically inhibits the functions of the CYP450 isozymes [97] [98] [99] [100] . However, in studies done in healthy volunteers, green tea only had a minor inhibitory effect on these isozymes, which may not be clinically significant [101, 102] . Nevertheless, caution should be taken when these herbs are used concomitantly with ACDs that are substrates of these enzymes. Plasma concentrations and pharmacological effects of the ACDs should be monitored in patients who concurrently consume these agents. A dose reduction recommendation is also provided for temsirolimus by the manufacturer when it is co-administered with strong CYP3A4 inhibitors [55] . Based on these interaction effects, precautions should be taken when patients are given herbal compositions that contain ginsengs, garlic and green tea [182] [183] [184] [185] [186] [187] [188] [189] .
ACD interactions with green tea also include increased risks of hematological effects and hepatotoxicity. In a case report of a 44-year-old man receiving warfarin prophylaxis secondary to mechanical valve replacement, the authors postulated that the vitamin K content in green tea could have caused an antagonistic action on the anticoagulant activity of warfarin [104] . The hematological properties of this CAM can be attributed to its anti-platelet properties which are comparable to aspirin as well [105] [106] [107] . Conversely, the hepatotoxicity of green tea is a result of the induction of oxidative stress in the liver by its epigallocatechin gallate component and its metabolites [108] . This constituent prevented bortezomib-induced tumor cell death in vitro and in vivo, resulting in a reduced efficacy of the ACD [103] . Thus, patients on bortezomib or ACDs with potentials of bleeding or liver injury should avoid consuming green tea concomitantly with their chemotherapy.
Blue-green algae (Spirulina platensis) has been demonstrated to have chemoprotective and radioprotective effects based on animal studies [190] , and may also be effective in the chemoprevention of various oral leukoplakias [191] . It was found to stimulate the immune system by potentiating macrophage functions, phagocytosis and interleukin (IL)-1 production in animals [49] , and has been included in a patent as a constituent of a herbal composition for immunocompromized conditions [185] . Spirulina may theoretically antagonize the immunosuppressive effects of corticosteroids, which are commonly used as antiemetic agents for the prophylaxis and treatment of chemotherapy-induced nausea and vomiting [192, 193] . Caution is advised in patients who are concurrently on these agents, with regular monitoring done to check for altered efficacy of the corticosteroids.
The anticancer effect of cassia bark (Cinnamomum sp.) is due to the induction of apoptosis by an active constituent, cinnamaldehyde [194] . Cassia bark contains another constituent, coumarin, which has been suggested to cause hepatotoxicity in animals, as well as in high doses (50-7000mg daily) in humans [51] . Chaparral (Larrea sp.), another herb with cytotoxic effects [195] , has also been reported to cause hepatotoxicity in several patients [57, 58] . The di-orthoguinone reactive intermediate derived from the biotransformation of nordihydroguaiaretic acid, the active constituent of chaparral, is responsible for its toxicity [171] . ACDs which have a potential risk of liver toxicity [50] should not be concurrently used with cassia bark or chaparral due to additive hepatotoxic effects. If concomitant use is unavoidable, monitoring of the patient's liver function (e.g. aspartate aminotransferase (AST or SGOT), alanine aminotransferase (ALT or SGPT) and bilirubin levels) and signs and symptoms of hepatotoxicity (e.g. jaundice) should be carried out. Special attention must be paid to trabectedin when it is co-administered with herbs which have hepatotoxic potential. The manufacturer recommends that dexamethasone must be given prior to trabectedin therapy due to its hepatoprotective effects, and specific dose adjustments are also provided [52, 53] .
Licorice (Glycyrrhiza sp.) is a widely used CAM for a variety of conditions and ailments, of which cancer is one of them. It has shown to exhibit chemopreventive effects against colon and breast cancers in vitro [196] , and inhibit tumor growth in mice [110] . Hence, it is of no surprise that many patents have included this herb as a component for use in cancer treatment and prevention [185, 186, [197] [198] [199] [200] . However, its combination with cisplatin resulted in a diminished therapeutic efficacy of the ACD [110] . In addition, licorice prevents the inactivation of cortisol through inhibition of 11-beta-dehydrogenase, resulting in hypokalemia, myopathy, and hypertension [111, 112] . Thus, an interaction between licorice and corticosteroids may also exist. Gladribin, a major isoflavan in the licorice root, competitively binds to estrogen receptors in vitro and may displace tamoxifen from estrogen receptors, causing altered pharmacological effects of the drug [113] . Thus, co-administration of these ACDs with licorice is not recommended. However, if concurrent use is warranted, monitoring of the pharmacological activities of the ACDs should be carried out, with additional monitoring of potassium levels if patients are on corticosteroid therapy.
Pharmacokinetic interactions that may occur with licorice involve ACDs that are substrates of CYP2B6, 2C9 and 3A4.
Licorice inhibits CYP2B6 in vitro [114] , but studies have not been consistent on its effects on the latter isozymes, suggesting that it has an inhibitory effect in vitro, but an induction effect in vivo [114, 115] . The triterpenoid glycyrrhizin, another constituent in licorice, induced the CYP3A isozymes in rats [116, 117] , but did not show any alterations in midazolam pharmacokinetics (a CYP3A4 substrate) in healthy male subjects [118] . Nonetheless, caution and close monitoring of plasma ACD levels should be taken when patients consume licorice with ACDs that are substrates of these isoenzymes.
Studies of milk thistle (Silybum marianum, Carduus marianum) have shown that it inhibits colon carcinogenesis [201] , induces growth inhibition and apoptosis in prostate cancer cells [202] , as well as works in synergism with conventional ACDs against breast carcinoma cells [203] . The anti-invasive and anti-metastatic activities of the flavonolignan silibinin (also known as silybin) from milk thistle, and the anti-carcinogenic and chemopreventive potentials of its active constituents silymarin and silipide (a formulation of silibinin and phospholipids), have supported its use as a chemotherapeutic agent [204, 205] . Silymarin, which consists of numerous flavonoligans such as silybin, isosilybin, silydianin and silychristin [206] , was found to offer another benefit of protection against cisplatin-based nephrotoxicity based on animal studies [207] , which may be attractive to its use in cancer therapy as well. This herb interacts pharmacokinetically with ACDs that are CYP2C9 and 3A4 substrates via inhibition of these isozymes [120] , thus plasma ACD levels should be monitored in patients who take milk thistle compositions [182, 188, 189] together with their chemotherapy. This is despite the fact that a study done on 12 healthy volunteers did not show any statistically significant effects on CYP3A4 [119] . The authors had postulated that the use of milk thistle posed minimal risk of CYP3A4-mediated interactions, but as the sample size of the study was small, the results should be interpreted with caution, especially in cancer patients who are, more often than not, on chemotherapy regimens consisting of multiple ACDs that are substrates of these isozymes. Soy (Glycine max) has been reported to reduce the risks of lung, prostate and endometrial cancers [208] [209] [210] . In contrast, its use in breast cancer is not well-established. This CAM is postulated to prevent breast cancer possibly due to the relatively low levels of methionine, which may limit the synthesis of polyamines needed for tumor growth [211] . Genistein, an isoflavone in soy, may also suppress the development of breast cancer in adulthood when exposed early in life [212] . However, studies have been inconsistent, with others suggesting that the isoflavones may also increase breast cancer risk due to its estrogenic properties [213] . Genistein interacts with tamoxifen, which may result in altered chemotherapeutic efficacy of the drug. Low concentrations of genistein may lead to an antagonism of the pharmacological effects of tamoxifen, but at high concentrations, the effects of tamoxifen may be enhanced [123] [124] [125] . In addition, high amounts of tyramine in soy and soy products (e.g. soybean, soy sauce, tofu) predispose patients to an increased risk of hypertensive crisis when used concomitantly with procarbazine therapy due to a decrease in the breakdown of tyramine [122] . Hence, patients should be advised to avoid concomitant use of soy products together with tamoxifen or procarbazine therapy. In addition, clinicians should also advise their patients regarding the potential risk of tumor growth when consuming soy products with tamoxifen due to failure of therapy.
IMMUNE-SYSTEM-RELATED
Many of the CAMs which are classified for cancer treatment and prevention also have immune-system-related effects, which partly account for their indication in cancer therapy Table 2 . For example, the immunomodulating effects of Astragalus membranaceus contribute to its role as an antitumor agent [214, 215] , but more recently, its sapo-nins which include astragalosides I to VIII, isoastragalosides I, II and IV, acetyl-astragaloside I, and soyasaponin I, were found to exhibit additional anticarcinogenic and proapoptotic activities in human cancer cells lines [216] . Its use also affords a protective function against daunorubicin-induced cardiotoxicity [217] , making it an attractive constituent for herbal compositions used in the treatment of cancer [183, 186, 200, 218] . Bitter melon (Momordica charantia) is another herb used in compositions for the treatment of immunocompromised conditions [185] , but it also possesses anticancer activity due to the presence of its conjugated linolenic acid constituents [219, 220] , as well as the MAP30 protein [221] . In addition, animal studies have suggested that its antitumor activity could be due to its immunomodulatory effects and direct interaction of some of its components with tumor cells [41] . In a recent study done in stage II or III cervical cancer patients treated with radiotherapy, there was some evidence of immune system response when bitter melon was consumed [42] . Cordyceps (Cordyceps sinensis), on the other hand, is a fungus which exhibits its immunoregulatory properties through the elevation of cytokines, particularly interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha [59, 60] . Ginseng, another herb previously mentioned, possesses immunoregulatory effects on top of its anticancer properties, possibly through increase in both cell-mediated and humoral responses by its ginsenoside Rg1 [222] . Since all these CAMs modulate the immune system in some way, caution is recommended during concurrent use with immunosuppressive drugs such as corticosteroids because of a theoretical possibility of an interaction occurring.
ALOPECIA
Alopecia is a common and distressing side effect for patients with cancer [223] . It can be either tumor-induced or chemotherapy-induced, and can vary in morphology [223, 224] . Among the CAMs that are indicated for use in hair loss, fenugreek was found to have pharmacodynamic interactions with ACDs. Fenugreek (Trigonella foenumgraecum) has demonstrated positive effects on hair growth in a recent randomized, placebo-controlled efficacy trial [225] , but its effects on alopecia associated with neoplasms and chemotherapy is still not well-established. As previously mentioned, this herb may interact with rituximab causing an increased risk of hypoglycemia [24, 25, 43, 44] . In addition, its concomitant use with ACDs that have hematological effects (e.g. dasatinib, ibritumomab, tositumomab) may prone patients to an increased risk of bleeding as well. In a published case report, the international normalized ratio (INR) of a patient treated with warfarin was increased during co-administration with boldo and fenugreek [66] . Thus, patients who are on combinations of fenugreek and these ACDs should be monitored for signs and symptoms of bleeding and hematological complications.
NAUSEA AND VOMITING
Chemotherapy-induced nausea and vomiting (CINV) causes extreme discomfort in patients with cancer and impairs their quality of life [226, 227] . CINV affects not only the patients' nutritional status, but also their ability to work and motivation to follow recommended treatment regimens [226, 227] . Although the effectiveness of ginger (Zingiberis rhizoma) [228] [229] [230] and peppermint (Mentha sp.) [231] [232] [233] [234] has been demonstrated in a variety of conditions associated with nausea and vomiting (e.g. morning sickness, pregnancy, chemotherapy-induced), and are commonly incorporated in compositions used for relieving CINV [235] , these studies have been limited. Both herbs are subjected to interactions with ACDs and clinicians should be aware of their interaction effects and know how to manage them.
Ginger has shown to improve hyperglycemia in diabetic rats [236] [237] [238] . Gingerol, its active constituent, exerts insulin sensitizing and insulin-sensitive glucose uptake-enhancing effects in adipocytes [239] . Hence, consumption of ginger when patients are on rituximab therapy may predispose them to a risk of hypoglycemia [24, 25] . Additionally, this CAM may also potentiate the risk of bleeding when coadministered with ACDs which have hematological side effects such as dasatinib, ibritumomab and tositumomab [75, 76] . On the other hand, peppermint inhibits the CYP1A2, 2C9, 2C19 and 3A4 isozymes in vitro [61] . Its inhibitory action on CYP3A4 was also published in a clinical study of 12 healthy volunteers co-administered with felodipine [121] . Hence, signs and symptoms of rituximab-induced hypoglycemia, increased bleeding, and increased plasma levels of ACDs which are substrates of these isozymes should be closely monitored in patients who are concomitantly on ginger and peppermint respectively.
PERIPHERAL NEUROPATHY AND PAIN
St. John's wort (Hypericum perforatum) has been used as an alternative medicinal herb for the treatment of pain associated with peripheral neuropathy [240] , but it is more commonly associated with its use as an antidepressant [241] . The compound responsible for its antidepressant effects is the phloroglucinol derivative, hyperforin [242] , although another constituent, hypericin, is a potent photosensitizer [243] . With regards to its use as a herbal treatment for pain, a clinical study by Sindrup and colleagues had showed a trend towards a lower pain score with St. John's wort compared to placebo even though the difference in scores were not statistically significant [240] . However, in the review by Head [244] , it was postulated that this was because the dose of St. John's wort was the lowest dosage recommended for depression treatment, and that higher dosages could possibly be helpful in the treatment of neuropathy.
There is an abundance of studies showing the interaction potential of St. John's wort, and the most established are its pharmacokinetic interactions involving the induction of the CYP3A4 [128, 132, 142] and 2C9 isozymes [146] , as well as p-glycoprotein [67, 147, 148] . Many ACDs are substrates of these enzymes, including several of the alkylating agents, antimicrotubules, hormone agonists/antagonists, topoisomerase inhibitors, and tyrosine kinase inhibitors, among others Table 4 . A decrease in therapeutic efficacy of the ACDs may result if these ACDs are taken together with St. John's wort. Clinicians should advise patients who are on these ACDs to refrain from taking this herb concurrently with their chemotherapy regimens, and to monitor the plasma concentrations of the ACDs and appropriately adjust the doses if their patients are already on these agents concurrently.
Pharmacodynamic interactions identified for St. John's wort were with procarbazine and thalidomide. An increased risk of serotonin syndrome and its associated adverse effects (e.g. hypertension, hyperthermia, agitation, confusion, and coma) exists with procarbazine due to its MAO inhibitory activity, and at least 14 days should elapse between use of the MAO inhibitor and St. John's wort [126, 127] . A case of a 35-year-old woman who developed subacute toxic neuropathy after ingesting St. John's wort (500mg daily for 4 weeks) [149] was also published additionally to other isolated cases of paresthesias and central nervous system (CNS)-related adverse events [150, 151] . Patients on concurrent therapy with thalidomide could suffer from an increased risk of CNS-related events, thus clinicians should monitor for related signs and symptoms in patients who take St. John's wort together with thalidomide.
Interactions can also occur between St. John's wort and photosensitizing agents (porfimer, temoporfin) or retinoids (alitretinoin, tretinoin) due to its photoactive hypericin component, leading to photosensitivity reactions and phototoxicity [152] [153] [154] [155] [156] [157] [161] [162] [163] [164] . However, results from studies have been inconsistent. Some studies showed no phototoxic potential when the herb was administered [158] , while others suggested no correlations between the photosensitivity reactions and total plasma Hypericum concentrations [157] . Yet others indicated that phototoxicity only occurred at high doses of hypericin [159, 160] . Nonetheless, patients on therapy with retinoids and photosensitizing agents should avoid co-administration of St. John's wort, and be advised to keep out of the sun, wear protective clothing outdoors and use a sunscreen if co-administration of these agents is unavoidable.
Increased bleeding risks and interactions with warfarin [75, 76] were also identified for St. John's wort and capsaicin. Capsaicin is used as an analgesic for surgical neuropathic pain in cancer patients [245] , and is produced by chilli peppers (Capsicum sp.). Capsicum species have also shown an anticancer effect in vitro [246, 247] . Patients on concurrent therapy with dasatinib and monoclonal antibodies could suffer from an increased risk of hematological-related side effects, and clinicians should advise patients to avoid these combinations, or monitor for related signs and symptoms if concomitant administration cannot be avoided.
INFLAMMATION
Willow bark (Salix alba) is a CAM which may play a role in the relief of pain and inflammation [168, 248, 249] . Although salicin, an active component, is metabolized in vivo to salicylic acid, studies have suggested that the analgesic and anti-inflammatory effects of willow bark may not be due to either salicin or salicylic acid alone [250, 251] . Willow bark is reported to have antiplatelet effects in humans but to a lesser extent than acetylsalicylate (aspirin) [167] , and has been associated with an increased risk of selfreported bleeding [75] . It manifests an interaction with warfarin and may potentiate an increased risk of bleeding [76] . Theoretically, it can also predispose patients to an increased risk of hematological adverse effects associated with dasatinib, ibritumomab and tositumomab.
On the other hand, comfrey (Symphytum officinale) is a medicinal herb which has been traditionally used for its antiinflammatory, analgesic and astringent properties [252] . It is carcinogenic in animals and hepatotoxic in both livestock and humans, due to the genotoxicity of the pyrrolizidine alkaloids that are in the herb [253] [254] [255] . In addition, these alkaloid constituents can cause hepatic injury and are also metabolized by the CYP3A isozymes to toxic metabolites [256] . In a published case of a 13-year-old boy diagnosed with Crohn's disease, ingestion of a herbal tea containing comfrey leaf led to veno-occlusive disease of the liver [257] . He presented with fatigue, diarrhea, and weight loss, followed by fever, abdominal pain and swelling a few weeks later. On examination, it was discovered that he had hepatomegaly and ascites, and increased serum bilirubin and AST levels. Clinicians should be aware of the carcinogenicity and hepatotoxicity potentials of comfrey, and this CAM should be strictly avoided in patients with cancer.
Other herbs used for treating inflammation include cat's claw (Uncaria tomentosa) and devil's claw (Harpagophytum procumbens). Cat's claw has antioxidant effects, as well as inhibitory action on the production of tumor necrosis factor (TNF)-alpha, a cytokine involved in inflammation [56, 258] . On the other hand, devil's claw not only prevents TNF-alpha release, but also suppresses the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide [62, 259] , which may play a role in its peripheral analgesic properties as well [260, 261] . These herbs and their herbal compositions [183] have been implicated to have immunomodulatory effects [56, 62] , and may interfere with corticosteroid treatment. in vitro Studies have reported that the pentacyclic and tetracyclic oxindole alkaloids in cat's claw alter the proliferation of lymphocytes [262] , while the major harpagoside component in devil's claw suppresses NF-kappaB [259] , which is a transcription factor found in immune cells involved in inflammatory and immune responses [263] . Thus, caution is advised and close monitoring for any changes in the effectiveness and safety of corticosteroid treatment is recommended.
Additionally, in vitro studies have suggested that cat's claw is a CYP3A4 inhibitor [54] , while devil's claw inhibits both CYP3A4 and the CYP2C subfamily of isozymes [61] . The biotransformation of ACDs that are substrates of these isozymes can be affected by interactions with these herbs. Severe paclitaxel toxicity was reported with co-administration of antiretroviral therapy due to inhibition of its CYP3A4-mediated metabolism by the antiretroviral agents [264] . Similarly, co-administration of itraconazole (a CYP3A4 inhibitor) with vincristine (a CYP3A4 substrate) has been associated with an increased risk of neurotoxicity in patients [265] . While no specific interactions have been reported for other taxanes and vinca alkaloids, HDIs with other ACDs in these classes should also be expected. The extent and significance of possible HDIs with herbs that are CYP3A4 inhibitors and other taxanes (e.g. docetaxel) [22, 24, 266, 267] and vinca alkaloids (e.g. vinblastine, vinorelbine, vindesine) [268] [269] [270] [271] should be taken into account during chemotherapy treatment. Ixabepilone, a new anticancer drug approved in the US in 2007, can also interact with CYP3A4 inhibitors [272, 273] . A clinical study done on 27 patients showed that ketoconazole significantly increased plasma levels of ixabepilone and the risk of neutropenia toxicity through inhibition of CYP3A4 [273] . The narrow therapeutic indices of these ACDs warrant close monitoring of plasma concentrations and potential toxicities of the ACDs, and appropriate dosage adjustments when applicable. Specific dose reduction recommendations have been provided in literature for temsirolimus (12.5mg/week) and ixabepilone (20-25mg/m 2 ) in the presence of strong CYP3A4 inhibitors, and clinicians are referred to these resources for further details [55, 273] .
The anti-inflammatory effect of gotu kola (Centella asiatica) is through the inhibition of pro-inflammatory mediators, such as COX-2, prostaglandin E2, TNF-alpha and IL-6, by the triterpenoid madecassoside [274] . This herb has been used as a constituent in herbal compositions for alleviating inflammation [182, 188, 189] and in a wide range of medical conditions including the treatment of wounds and venous insufficiency [92, 275] . It is hepatotoxic [91] and may potentiate the risk of liver damage when used concomitantly with ACDs which have a hepatotoxic risk. In addition, it appears to exhibit immunomodulatory and CNSrelated effects, although strong clinical studies are lacking [92] . In fact, there has been contradictory evidence on the CNS depressant effects of gotu kola. This herb was found to increase pentobarbitone-induced sleeping time in animals [93] , and is indicated as a dietary supplement for sleep disorders [94] . However, a recent study done by Wijeweera et al. [95] showed that its active component, the triterpenoid asiaticoside, did not affect locomotor activity in rats, and thus the authors suggested that gotu kola might not have any sedative effects. Gotu kola may precipitate a CNS depression interaction with paclitaxel caused by the alcohol content in the paclitaxel formulation [25, 96] . Clinicians should be aware of the hepatotoxic and CNS-depressant effects of this herb, so that monitoring of the patient's liver function, and signs and symptoms of hepatotoxicity and CNS depression can be carried out if patients concurrently take this herb with their chemotherapy.
FATIGUE SYNDROME
Fatigue syndrome is a common management problem in cancer patients [276] and may be correlated with other medical conditions faced by cancer sufferers, such as insomnia, anxiety and depression, which may lead to a poorer quality of life [277] . As such, patients who are advocates of CAMs may look for herbal therapies to help relieve their fatigue in an attempt to improve their quality of life.
Several herbs have claimed to be useful in the relief of fatigue. Among them, guarana (Paullinia cupana) has been reported to improve both cognitive performance and mental fatigue [278] . However, a study done on breast cancer patients undergoing radiation therapy administered with guarana did not demonstrate any statistically significant differences in the relief of post-radiation fatigue [279] . In contrast, maté (Ilex paraguariensis) is a medicinal herb that offers multiple pharmacological effects, including CNS stimulation, antioxidation and hepatoprotection, among others [280] . The stimulatory and anti-fatigue properties of maté have been identified to be due to the xanthenes (caffeine, theobromine) and pantothenic acid respectively [280] . Thus, it can possibly be effective as a herb to combat mental and physical fatigue [281] . Notwithstanding the benefits of maté in the treatment of fatigue, its anticancer properties have been conflicting. Maté was demonstrated to be protective against DNA oxidation and cytotoxic to human cancer hepatoma cells (HepG2) [282, 283] , but epidemiological studies have suggested an association between consumption of maté and increased risks of developing certain cancers (e.g. head and neck, esophageal, lung, and renal) [284] [285] [286] , possibly due to its high concentrations of poly-cyclic aromatic hydrocarbons [287] .
Both herbs were identified in our search to manifest interactions with procarbazine-based chemotherapy due to the high caffeine content present, which leads to an increased risk of patients suffering from hypertensive crisis [109] . Patients may present with clinical signs and symptoms of increased blood pressure, confusion and restlessness, thus concomitant use of these agents is not recommended.
CAMS
USED IN OTHER CONDITIONS EXPERIENCED BY PATIENTS WITH CANCER
Several CAMs that may be used by cancer patients for other conditions are described in this section. These CAMs deserve mention because of their HDI potentials with ACDs. They are mainly black cohosh, dong quai, ginkgo and valerian.
Black cohosh (Cimicifuga racemosa) is a herb that is widely used by breast cancer patients to alleviate menopausal symptoms, particularly hot flashes by acting as an estrogen in the brain and on neurotransmitter systems. However, the active constituents responsible for this effect and its exact mechanism remains unknown, and the evidence on its efficacy has been inconsistent [288] . in vitro Studies have shown that black cohosh decreased the cytotoxicity of cisplatin, but increased the cytotoxicities of doxorubicin and docetaxel in mouse breast cancer cell lines [45] . Furthermore, this herb weakly inhibits CYP2D6 in vivo and may affect the metabolism of ACDs that are substrates of this isozyme, such as doxorubicin, lomustine and tamoxifen, leading to increased plasma ACD concentrations [47] . For tamoxifen, this may lead to decreased levels of its active metabolite, endoxifen, which may in turn result in reduced efficacy of the drug [48] . By contrast, the proliferationinhibiting effect of tamoxifen was additively enhanced by black cohosh in estrogen receptor-positive breast cancer cells [46] . Hence, clinicians should exercise caution when their patients are on these agents and black cohosh concurrently. Plasma levels and pharmacological effects of the ACDs should be closely monitored. An anti-neoplastic composition containing extracts of black cohosh was identified from our list of patent compositions [289] . Users of this herbal composition should be mindful of the possible interactions that can possibly occur when combined with chemotherapies that contain these ACDs. Dong quai (Angelica sinensis) is another Chinese herb that is commonly used in the treatment of menstrual cramps, irregular menses, and hot flashes in menopause [65, 290] . In addition to these effects, this herb was also demonstrated to have anticancer activity by inhibiting the growth of malignant brain tumor cells [291] ; and its polysaccharides was shown to possess anti-tumor effects on experimental in vivo models and inhibitory effects on invasion and metastasis of hepatocellular carcinoma cells in vitro [292] . Besides a pharmacokinetic interaction involving an increase in CYP2D6 and 3A activities [63] , it additionally manifests a pharmacodynamic interaction which leads to an increased risk of bleeding [65] . The HDI effect with tamoxifen is less clear. Dong quai may increase CYP450-mediated metabolism of tamoxifen to endoxifen, its active metabolite, yet antagonize the anti-estrogenic activity of the ACD [63, 64] . Consequently, we recommend that proper precautionary measures be taken when patients are concurrently taking dong quai with tamoxifen, CYP2D6 and 3A substrates, or drugs which have effects on the hematological system. The use of ginkgo (Ginkgo biloba) in conjunction with fluorouracil in advanced progressive colorectal cancer patients has been evaluated in a phase II study, which reported that patients who were on the combined ginkgofluorouracil therapy had a good benefit-risk ratio [293] . The authors hypothesized that this combined therapy could be efficacious in cancer treatment because ginkgo did not only provide antioxidant effects, but also increased local blood flow. However, the number of patients who benefited from this combination therapy was small (2 cases of partial response and 8 cases of stable disease after at least 2 cycles of therapy), and further studies for its efficacy are warranted. Ginkgo affects the activity of several CYP isozymes. Studies done on rats have suggested that bilobalide, the main active component of ginkgo, is responsible for its induction of the CYP450 isozymes, particularly of the CYP2B isoform [78, 294] . Furthermore, human studies have shown that it induces CYP2C19 [77] , while in vitro studies have suggested that it inhibits CYP2C9 [79] . However, there is contradictory evidence on its effects on CYP3A4. in vitro Studies have suggested a moderate inhibition of CYP3A4 by the herb extract [79] , yet other studies have indicated differential induction potentials of its terpenoids and flavonoids on the same isozyme [80] . Nevertheless, monitoring of plasma levels and clinical efficacy of ACDs is recommended when ginkgo and its compositions [182, 188, 189] are coadministered with substrates of CYP2C9, 2C19 and 3A4. In addition, high concentrations of ginkgo may potentiate the MAO inhibitory activity of procarbazine [81] . Concomitant use of ginkgo with procarbazine is not recommended, but for patients already on this combination, signs and symptoms of CNS toxicity (e.g. paresthesias, neuropathies, and confusion) should be closely monitored.
As previously mentioned, cancer patients often suffer from anxiety and depression which significantly affects their quality of life [277] . Besides the use of St. John's wort, valerian (Valeriana officinalis) is another herb that is able to relief anxiety and restlessness because of increased responses to gamma-aminobutyric acid (GABA) due to its content of the sesquiterpenes valerenic acid and valerenol [295] . As with St. John's wort, potential interactions involving the inhibition of CYP3A4 can potentially occur between valerian and ACDs that are substrates of this isozyme [165, 166] . This herb increased the area under the plasma concentration-time curve of alprazolam (a CYP3A4 substrate) by approximately 20% in an open-label, cross-over study of healthy volunteers [166] . However, the authors suggested that the increase was unlikely to be clinically relevant. Thus, it may seem that this herb is safer compared to St. John's wort for consumption by cancer patients suffering from anxiety. Still, caution should be taken with proper monitoring of plasma levels and pharmacological effects of the ACDs.
LIMITATIONS OF THIS REVIEW
This review is not without its own limitations. ACD-CAM interactions, especially those of TCM herbs, are relatively less well-established compared to interactions with conventional western medications. Under the circumstances, the majority of the HDIs mentioned in this review were based on animal and in vitro metabolic studies, as well as published case reports. Furthermore, only studies that were published in English, either in abstract form or full text, were included in this review. In spite of the limited studies available on HDIs, we included some HDIs that were based on similar metabolic pathways (e.g. induction and inhibition of CYP450 isozymes) and class effects (e.g. vinca alkaloids, corticosteroids) so as to increase the awareness of such interactions among clinicians and healthcare professionals dealing with cancer patients in their practice. This strategy not only allows them to obtain a broader perspective of potential interactions that can occur with CAMs, but will hopefully help in improving treatment outcomes through the avoidance of these herb-drug combinations.
CURRENT & FUTURE DEVELOPMENTS
The prevalence of CAM use in patients with cancer is high, particularly in Asian countries [296] [297] [298] [299] . These patients often turn to the use of CAMs as alternative forms of supportive care, particularly those who have a poorer prognosis of the disease [300] . Cancer treatment often comprises of multidrug-combination chemotherapeutic regimens, which increases the risk for ACD-CAM interactions. Clinicians should be aware of these interactions to better manage their patients.
The development of the Human Genome Project and the International HapMap Project has led to advances in pharmacogenetics and pharmacogenomics [301] , which has benefited the field of oncology in its quest for personalized medicine [302] . The Human Epigenome Project [303] has also resulted in interests in other specialty fields such as pharmacoepigenetics [304] and pharmacoepigenomics [305] . As ongoing research continues to target the human proteome, interactome, and metabolome, hopefully more data will be known to allow further understanding of ACD interactions. The use of CAMs as adjuncts (or even substitutes) to conventional chemotherapy in patients with cancer is becoming increasingly popular. This trend, together with the development of in silico methods of docking and modelling, imply that the evidences of HDIs and their mechanisms of interactions will become stronger with time. Clinicians can then appropriately manage these HDIs in their patients based on these newer studies. However, as of now, our knowledge on ACD-CAM interactions can only be based on in vitro and in vivo studies, reported cases and small-scale clinical studies that have been documented in literature. As such, due to the limited clinical experience with concomitant use of ACDs and CAMS in current practice, clinicians are encouraged to submit case reports if they suspect an ACD-CAM HDI.
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